“When times are good, people don’t sell their blood to CSL,” he said. Indeed, the average 12-month price target is well above today’s price tag at $333, implying CSL is a steal at $307. Sixteen, or 84 per cent, of analysts surveyed by Bloomberg, have a “buy” rating on the company.